v
Search
Advanced Search
  • Newly published articles
  • Highlights
    Review Article Open Access
    Tunisian Nephroprotective Plants: A Review
    Wissem Aidi Wannes, Moufida Saidani Tounsi
    Journal of Exploratory Research in Pharmacology, Published online September 21, 2022. doi:10.14218/JERP.2022.00031
    Abstract
    In Tunisian folk medicine, several herbs are prescribed for reducing renal damage and to avoid kidney related complications. These can be of immense value in combating renal damage. [...] Read more.
    In Tunisian folk medicine, several herbs are prescribed for reducing renal damage and to avoid kidney related complications. These can be of immense value in combating renal damage. In this review, we provide a description of the current literature on the use of indigenous herbs as alternative medicine for treating renal damage. The aim of this review was to collect information on promising active phytoconstituents such as organosulfur compounds, polyphenols, terpenes, alkaloids phenylpropanoids, and polysaccharides from Tunisian plants that have been scientifically examined for their nephroprotective capacities. Twenty-nine Tunisian medicinal plants have been reported for their significant nephroprotective activities against renal toxicities in animal models. Lamiaceae was the most commonly used Tunisian plant family used for renal protection. The leaves were maximally used for nephroprotection compared to the other plant parts. Nephrotoxicity is commonly the result of several nephrotoxins. Many studies have focussed on drug-caused renal failure which is one of the major problems in medical practice. Other studies focused on other important nephrotoxicity factors, including drugs and industrial chemicals. This literature review highlights the use of some medicinal plants as nephroprotective agents. To defend against this nephrotoxicity, some medicinal plants, known as nephroprotective agents, have been highlighted in this review. Full article
    Review Article Open Access
    Ustekinumab in Pediatric Dermatology: An Updated Review
    Ahmed Samaouel Chehad, Nada Boutrid, Hakim Rahmoune
    Journal of Exploratory Research in Pharmacology, Published online September 16, 2022. doi:10.14218/JERP.2022.00045
    Abstract
    Managing chronic pediatric skin disorders is challenging due to a lack of approved medication and the relative weakness of research studies for this age group. Ustekinumab is a human [...] Read more.
    Managing chronic pediatric skin disorders is challenging due to a lack of approved medication and the relative weakness of research studies for this age group. Ustekinumab is a human monoclonal antibody that targets the p40 subunit shared by IL12 and IL23 and thereby modulates the inflammatory reaction triggered by the Th1 and Th17 pathways, respectively. Currently, in dermatology, ustekinumab is the only IL12/IL23 inhibitor approved by regulatory authorities to treat moderate to severe psoriasis in adults, adolescents, and children of age six years and older. Although off-label and not supported by strong evidence, the therapeutic use of ustekinumab has been gradually extended to various other dermatoses. The reported adverse events of this biologic in pediatric patients were generally consistent with those in adults. However, its long-term safety remains to be confirmed. In this review, we discuss the existing evidence on the mechanisms of ustekinumab action, the current regulatory authority-approved indications, off-label use in pediatric cutaneous disorders, and the most reported adverse events related to this drug. Full article
    Original Article Open Access
    Aberrant Expression of BLM Correlates with Malignant Progression and Immune Infiltration in Pancreatic Adenocarcinoma
    Quan Li, Pan Zhang, Yu-Ni Zhang, Hui-Xiao Hu, Jun-Fang Yan, Ai-Hua Shen, Bu-Rong Hu
    Cancer Screening and Prevention, Published online September 16, 2022. doi:10.14218/CSP.2022.00015
    Abstract
    Pancreatic adenocarcinoma (PAAD) is a common malignancy in the digestive tract. Emerging studies have reported that Bloom’s syndrome helicase (BLM) is closely associated with the tumor [...] Read more.
    Pancreatic adenocarcinoma (PAAD) is a common malignancy in the digestive tract. Emerging studies have reported that Bloom’s syndrome helicase (BLM) is closely associated with the tumor prognosis and immune microenvironment. Our study aimed to reveal BLM’s potential prognosis value in PAAD. Potential oncogenic effects and prognostic influence of BLM were explored based on the TCGA and GETx databases. Gene mutation and methylation analyses were performed on the cBioPortal website and SMART database. The ARCHS4 and JASPAR2022 databases were used to predict the upstream transcription factor targets (TFs) of BLM. Starbase was used to explore the upstream ncRNAs. The relationship of BLM with the PAAD immune infiltration and immune checkpoints was analyzed using TIMER and GEPIA databases. BLM was highly expressed and correlated with a poor prognosis in PAAD. The hypomethylation of BLM was observed in PAAD and correlated with a poor prognosis. The predicted TFs (E2F1 and ETS1) were also highly expressed and positively correlated with a poor prognosis in PAAD. LINC01133-miR-30b-5p axis was explored to be the most potential upstream ncRNAs of BLM in PAAD. Furthermore, the BLM expression was positively correlated with the PAAD immune infiltration cells. The BLM expression was also positively correlated with the expression of the immune checkpoints of PD1, PD-L1, CTLA-4, and CD47. The high expression of BLM was associated with the poor prognosis of PAAD. In addition, a high BLM expression could facilitate the expression of the immune checkpoints in the immune infiltration cells, which would promote PAAD progression and affect its prognosis. Full article
All Journals
  • Most viewed
  • Most cited
    Review Article Open Access
    Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update
    Kristina Duspara, Kristina Bojanic, Josipa Ivanusic Pejic, Lucija Kuna, Tea Omanovic Kolaric, Vjera Nincevic, Robert Smolic, Aleksandar Vcev, Marija Glasnovic, Ines Bilic Curcic, Martina Smolic
    Journal of Clinical and Translational Hepatology, Published online September 13, 2021. doi:10.14218/JCTH.2021.00065
    Abstract
    Liver fibrosis is a life-threatening disease, with challenging morbidity and mortality for healthcare systems worldwide. It imparts an enormous economic burden to societies, making [...] Read more.
    Liver fibrosis is a life-threatening disease, with challenging morbidity and mortality for healthcare systems worldwide. It imparts an enormous economic burden to societies, making continuous research and informational updates about its pathogenesis and treatment crucial. This review′s focus is on the current knowledge about the Wnt signaling pathway, serving as an important pathway in liver fibrosis development and activation of hepatic stellate cells (HSCs). Two types of Wnt pathways are distinguished, namely the ß-catenin-dependent canonical and non-canonical Ca2+ or planar cell polarity (PCP)-dependent pathway. The dynamic balance of physiologically healthy liver and hepatocytes is disturbed by repeated liver injuries. Activation of the ß-catenin Wnt pathway prevents the regeneration of hepatocytes by the replacement of extracellular matrix (ECM), leading to the appearance of scar tissue and the formation of regenerated nodular hepatocytes, lacking the original function of healthy hepatocytes. Therefore, liver function is reduced due to the severely advanced disease. Selective inhibition of ß-catenin inhibits inflammatory processes (since chemokines and pro-inflammatory cytokines are produced during Wnt activation), reduces growth of activated HSCs and reduces collagen synthesis and angiogenesis, thereby reducing the progression of liver fibrosis in vivo. While the canonical Wnt pathway is usually inactive in a physiologically healthy liver, it shows activity during cell regeneration or renewal and in certain pathophysiological conditions, such as liver diseases and cancer. Targeted blocking of some of the basic components of the Wnt pathway is a therapeutic approach. These include the frizzled transmembrane receptor (Fz) receptors using the secreted frizzled-related protein family (sFRP), Fz-coreceptors low-density LRP 5/6 through dickkopf-related protein 1 (DKK1) or niclosamide, glycogen kinase-3 beta (GSK-3β) using SB-216763, cyclic-AMP response element-binding protein (CBP) using PRI-724 and ICG-001, the lymphoid enhancer binding factor (LEF)/T cell-specific transcription factor (TCF) system as well as Wnt inhibitory factor 1 (WIF1) and miR-17-5p using pinostilbene hydrate (PSH). Significant progress has been made in inhibiting Wnt and thus stopping the progression of liver fibrosis by diminishing key components for its action. Comprehending the role of the Wnt signaling pathway in liver fibrosis may lead to discovery of novel targets in liver fibrosis therapeutic strategies’ development. Full article
    Original Article Open Access
    Prognostic Nomogram for Patients with Hepatitis E Virus-related Acute Liver Failure: A Multicenter Study in China
    Jian Wu, Cuifen Shi, Xinyu Sheng, Yanping Xu, Jinrong Zhang, Xinguo Zhao, Jiong Yu, Xinhui Shi, Gongqi Li, Hongcui Cao, Lanjuan Li
    Journal of Clinical and Translational Hepatology, Published online May 6, 2021. doi:10.14218/JCTH.2020.00117
    Abstract
    Timely and effective assessment scoring systems for predicting the mortality of patients with hepatitis E virus-related acute liver failure (HEV-ALF) are urgently needed. The present [...] Read more.
    Timely and effective assessment scoring systems for predicting the mortality of patients with hepatitis E virus-related acute liver failure (HEV-ALF) are urgently needed. The present study aimed to establish an effective nomogram for predicting the mortality of HEV-ALF patients. The nomogram was based on a cross-sectional set of 404 HEV-ALF patients who were identified and enrolled from a cohort of 650 patients with liver failure. To compare the performance with that of the model for end-stage liver disease (MELD) scoring and CLIF-Consortium-acute-on-chronic liver failure score (CLIF-C-ACLFs) models, we assessed the predictive accuracy of the nomogram using the concordance index (C-index), and its discriminative ability using time-dependent receiver operating characteristics (td-ROC) analysis, respectively. Multivariate logistic regression analysis of the development set carried out to predict mortality revealed that γ-glutamyl transpeptidase, albumin, total bilirubin, urea nitrogen, creatinine, international normalized ratio, and neutrophil-to-lymphocyte ratio were independent factors, all of which were incorporated into the new nomogram to predict the mortality of HEV-ALF patients. The area under the curve of this nomogram for mortality prediction was 0.671 (95% confidence interval: 0.602–0.740), which was higher than that of the MELD and CLIF-C-ACLFs models. Moreover, the td-ROC and decision curves analysis showed that both discriminative ability and threshold probabilities of the nomogram were superior to those of the MELD and CLIF-C-ACLFs models. A similar trend was observed in the validation set. The novel nomogram is an accurate and efficient mortality prediction method for HEV-ALF patients. Full article
    Original Article Open Access
    Underlying Causes of Death among Adults in the United States, 2013–2017
    Xin Hu, Yong Lin, Gangjian Qin, Lanjing Zhang
    Exploratory Research and Hypothesis in Medicine, Published online December 1, 2020. doi:10.14218/ERHM.2020.00065
    Abstract
    Overall mortality among U.S. adults has been stable in past years; however, racial disparity influenced 10 leading causes of death or age-specific mortality in Blacks or African Americans. [...] Read more.
    Overall mortality among U.S. adults has been stable in past years; however, racial disparity influenced 10 leading causes of death or age-specific mortality in Blacks or African Americans. Unfortunately, the trends in sex- and race-adjusted age-standardized cause-specific mortality are poorly understood. We here aimed to identify the underlying causes of death (UCD) with sex- and race-adjusted, and age-standardized mortality that has changed in recent years. We extracted the data of UCD from the Multiple Cause of Death database of the Centers for Disease Control and Prevention (CDC). Multivariable log-linear regression models were used to estimate trends in sex- and race-adjusted, and age-standardized mortality of UCD during 2013–2017. A total of 31,029,133 deaths were identified. Among the list of 113 UCDs compiled by the CDC, there were 29 UCDs exhibiting an upward trend, 33 UCDs exhibiting a downward trend and 56 UCDs with no significant trends. The 2 UCDs with the largest annual percent change were both nutrition related (annual percent change [APC] = 17.73, 95% CI [15.13–20.33] for malnutrition, and APC = 17.49, 95% CI [14.94–20.04] for Nutritional deficiencies), followed by accidental poisoning and exposure to noxious substances. The 4 UCDs with the largest decreasing APC were viral hepatitis (APC = −11.71), chronic and unspecified bronchitis (APC = −8.26), emphysema (APC = −7.11) and human immunodeficiency virus disease (APC = −7.10). This study thus reports UCDs with changing mortality in recent years after sex- and race-adjustments and age-standardizations. More effort and resources should focus on understanding, preventing and controling the mortality linked to these UCDs. Continuous monitoring of mortality trends is recommended. Full article
Special Features

Call for Papers for Special Issue 'Frontier research on the toxicity and efficacy of Chinese medicine'

Journal: Future Integrative Medicine
Special Issue: Frontier research on the toxicity and efficacy of Chinese medicine
Submission deadline: December 31, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘A Spotlight on Progress and Pitfalls in NAFLD/MAFLD Studies, 2022’

Journal: Journal of Clinical and Translational Hepatology
Special Issue: A Spotlight on Progress and Pitfalls in NAFLD/MAFLD Studies, 2022
Submission deadline: 31 January, 2023
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Novel Therapeutic Interventions for Neurodegenerative Disorders’

Journal: Journal of Exploratory Research in Pharmacology
Special Issue: Novel Therapeutic Interventions for Neurodegenerative Disorders
Submission deadline: November 30, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Integrative Omics Study for Clinical Liver Disease’

Journal: Journal of Clinical and Translational Hepatology
Special Issue: Integrative Omics Study for Clinical Liver Disease
Submission deadline: October 31, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue 'Comparative study of traditional medicine in the world'

Journal: Future Integrative Medicine
Special Issue: Comparative study of traditional medicine in the world
Submission deadline:
Abstract Submission:June 1, 2022
Manuscript Submission: December 31, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue 'Therapeutic effects of herbal medicines on neurological impairment and related mental disorders based on the evidence of clinical and basic studies'

Journal: Future Integrative Medicine
Special Issue: Therapeutic effects of herbal medicines on neurological impairment and related mental disorders based on the evidence of clinical and basic studies
Submission deadline:
Abstract Submission:June 1, 2022
Manuscript Submission: December 31, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue 'Therapeutic strategies involving herbal medicines and bioactive ingredients for viral infections and secondary critical illness: interventions for inflammatory response and organ protection'

Journal: Future Integrative Medicine
Special Issue: Therapeutic strategies involving herbal medicines and bioactive ingredients for viral infections and secondary critical illness: interventions for inflammatory response and organ protection
Submission deadline:
Abstract Submission:June 1, 2022
Manuscript Submission: December 31, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Immunoregulatory Mechanisms of Herbal Medicines in Cancer and Infectious Diseases’

Journal: Future Integrative Medicine
Special Issue: Immunoregulatory Mechanisms of Herbal Medicines in Cancer and Infectious Diseases
Submission deadline:
Abstract Submission:June 1, 2022
Manuscript Submission: December 31, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Plant bioactives and their impact on psychological and cardiometabolic health’

Journal: Exploratory Research and Hypothesis in Medicine
Special Issue: Plant bioactives and their impact on psychological and cardiometabolic health
Submission deadline: October 31, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Natural active ingredient–based nanodrug delivery system for cancer treatment’

Journal: Journal of Exploratory Research in Pharmacology
Special Issue: Natural active ingredient–based nanodrug delivery system for cancer treatment
Submission deadline: October 31, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Artificial Intelligence in Liver Disease- Step towards Precision Medicine’

Journal: Journal of Clinical and Translational Hepatology
Special Issue: Artificial Intelligence in Liver Disease- Step towords Precision Medicine
Submission deadline: July 31, 2022
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Acute liver failure (ALF)’

Journal: Journal of Clinical and Translational Hepatology
Special Issue: Acute liver failure (ALF)
Submission deadline: August 31, 2021
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Metabolic dysfunction-associated fatty liver disease (MAFLD)’

Journal: Journal of Clinical and Translational Hepatology
Special Issue:Metabolic dysfunction-associated fatty liver disease (MAFLD)
Submission deadline: May 31, 2021
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Coronavirus Disease (COVID-19) and the Liver’

Journal: Journal of Clinical and Translational Hepatology
Special Issue: Coronavirus Disease (COVID-19) and the Liver
Submission deadline: June 30, 2021
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Prevention & Control of Coronavirus Disease (COVID-19)

Journal: Exploratory Research and Hypothesis in Medicine
Special Issue: Prevention & Control of Coronavirus Disease (COVID-19)
Submission deadline: June 30, 2021
Publication date: An article will be published online as soon as it is accepted

Call for Papers for Special Issue ‘Treatment of Coronavirus Disease (COVID-19)’

Journal: Journal of Exploratory Research in Pharmacology
Special Issue: Treatment of Coronavirus Disease (COVID-19)
Submission deadline: June 30, 2021
Publication date: An article will be published online as soon as it is accepted